Amalgamated Financial’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Amalgamated Financial’s Portfolio ITCI Stock Details ITCI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	$806K	Buy	+13,172	New	+$684K	0.01%	1288

Other funds holding ITCI

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Amalgamated Financial's ITCI Position: Q1 2022 in Review

Amalgamated Financial opened a new position in Intra-Cellular Therapies Inc. (ITCI) in Q1 2022: 13,172 shares worth $806K. The stake represents 0.01% of the portfolio and ranks #1288 among its holdings.

241 funds tracked by Wall St. Rank hold ITCI as of Q1 2022.

Amalgamated Financial held 13,172 shares of Intra-Cellular Therapies Inc. worth $806K as of Q1 2022.
Intra-Cellular Therapies Inc. was a new Amalgamated Financial position in Q1 2022.
Intra-Cellular Therapies Inc. made up 0.01% of Amalgamated Financial's portfolio in Q1 2022, its #1288 holding.
241 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.